Clinician Confidence May Shape Access to High‑Tech Treatments
Key takeaways
- Medicare Advantage patients with end‑stage kidney disease saw lower transplant and wait‑list rates than those on traditional Medicare, suggesting system‑level barriers may limit access to high‑value care [1].
- Cancer vaccines are beginning to improve outcomes in melanoma, but their broader use will depend on how easily clinicians can add them to existing chemo‑ and immunotherapy plans [2].
- Nurses who rate themselves high in innovative self‑efficacy—confidence in creative problem‑solving—are far more ready to adopt telehealth, highlighting the role of personal confidence in technology uptake [3].
How technology readiness affects kidney transplant access
Kidney transplantation offers better survival and quality of life than long‑term dialysis [1]. After the 21st Century Cures Act expanded Medicare Advantage (MA) eligibility for patients with end‑stage kidney disease, researchers found that MA enrollees had fewer transplants. Listing for a transplant was 3.05 per 1,000 person‑months for MA patients versus 4.64 for traditional Medicare patients, a relative rate of 0.77 [1]. Among those already on a wait list, MA patients received transplants at 16.59 per 1,000 person‑months compared with 20.85 for traditional Medicare, a relative rate of 0.91 [1].
The authors call for policy oversight to monitor equity as the MA population grows [1].
Cancer vaccines move from research to practice
Tumor vaccines have long struggled to show clinical benefit, but recent advances have identified more than 2,000 tumor antigens and clarified the immune responses needed for tumor eradication [2]. In a trial of stage IIIB to IV cutaneous melanoma, adding a vaccine to pembrolizumab (a checkpoint inhibitor) raised relapse‑free survival to 76.6% versus 60% with pembrolizumab alone; the hazard ratio was 0.56, with a confidence interval of 0.31‑1.02 and a p‑value of .05 [2].
Adverse effects from these vaccines are generally mild and brief, which may ease clinicians’ concerns about safety when combining vaccines with chemotherapy or immunotherapy [2].
Self‑efficacy drives telehealth adoption
A study of Saudi nurses examined telehealth readiness (TR) and its link to innovative self‑efficacy (ISE) [3]. Using Bandura’s Self‑Efficacy Theory and Davis’s Technology Acceptance Model, researchers found that nurses with higher ISE scores reported substantially greater TR [3]. In multivariable analysis, ISE emerged as the dominant independent predictor of readiness, even after accounting for age, education, and work experience [3].